Evidence map›Paper›PMID 31776284›Full record

ArticleJournal of virology2020

A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities.

Jeffrey R Schneider, Xiaoying Shen, Chiara Orlandi, Tinashe Nyanhete, Sheetal Sawant, Ann M Carias, Archer D Smith, Neil L Kelleher, Ronald S Veazey, George K Lewis and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. MUC16: clinical targets with great potential.Clinical and experimental medicine · 2024
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jeffrey R SchneiderDepartment of Microbial Pathogens and Immunity, Rush University Medical Center, Chicago, Illinois, USA.
Xiaoying ShenDepartment of Medicine, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-8387-3952
Chiara OrlandiDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Tinashe NyanheteDepartment of Immunology, Duke University, Durham, North Carolina, USA.
Sheetal SawantDepartment of Medicine, Duke University, Durham, North Carolina, USA.
Ann M CariasDepartment of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Archer D SmithProteomic Center of Excellence, Northwestern University, Evanston, Illinois, USA.
Neil L KelleherDepartment of Chemistry, Northwestern University, Evanston, Illinois, USA.
Ronald S VeazeyTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA.
George K LewisDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Georgia D TomarasDepartment of Surgery, Duke University, Durham, North Carolina, USA.
Thomas J HopeDepartment of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA thope@northwestern.edu.ORCID 0000-0001-7183-8319
Duke University · USNorthwestern University · USUniversity of Maryland, Baltimore · USRush University Medical Center · USTulane University · US

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Physical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1M
Project 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GALLO, ROBERT C · 2016 to 2019
$14.4M
TR&D 7: Cell Specific ProteomicsP41GM108569 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2015 to 2024
$13.6M
Harnessing MUC16-IgG Interactions to Enhance HIV Vaccine FunctionR01AI125171 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HOPE, THOMAS · 2016 to 2020
$2.9M
Understanding the mechanism(s) of systemic antibody delivery, distribution, and localization to mucosal sites in the in vivo macaque modelK01OD026571 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CARIAS, ANN M · 2018 to 2020
$1.1M
The role of steady state broadly neutralizing antibody tissue levels in preventing distal site SHIV replicationK01OD024882 · OD · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JEFFREY R · 2017 to 2019
$1.0M
NIAID NIH HHS P01 AI120756NIAID NIH HHS P01 AI124912NIAID NIH HHS R01 AI125171NIGMS NIH HHS P41 GM108569NIH HHS K01 OD024882NIH HHS K01 OD026571NIH HHS P51 OD011104
6 · The paper itself

Abstract

We have recently shown that MUC16, a component of the glycocalyx of some mucosal barriers, has elevated binding to the G0 glycoform of the Fc portion of IgG. Therefore, IgG from patients chronically infected with human immunodeficiency virus (HIV), who typically exhibit increased amounts of G0 glycoforms, showed increased MUC16 binding compared to uninfected controls. Using the rhesus macaque simian immunodeficiency virus SIVmac251 model, we can compare plasma antibodies before and after chronic infection. We find increased binding of IgG to MUC16 after chronic SIV infection. Antibodies isolated for tight association with MUC16 (MUC16-eluted antibodies) show reduced FcγR engagement and antibody-dependent cellular cytotoxicity (ADCC) activity. The glycosylation profile of these IgGs was consistent with a decrease in FcγR engagement and subsequent ADCC effector function, as they contain a decrease in afucosylated bisecting glycoforms that preferentially bind FcγRs. Testing of the SIV antigen specificity of IgG from SIV-infected macaques revealed that the MUC16-eluted antibodies were enriched for certain specific epitopes, including regions of gp41 and gp120. This enrichment of specific antigen responses for fucosylated bisecting glycoforms and the subsequent association with MUC16 suggests that the immune response has the potential to direct specific epitope responses to localize to the glycocalyx through interaction with this specific mucin.

Indexed as

AIDS VaccinesAnimalsAntibodies, ViralAntibody-Dependent Cell CytotoxicityCA-125 AntigenEpitopesHumansImmunoglobulin GMembrane ProteinsMucinsSimian Immunodeficiency VirusAIDS VaccinesAntibodies, ViralCA-125 AntigenEpitopesImmunoglobulin GMembrane ProteinsMUC16 protein, humanMucinsantibodiesmucosal immunologySIV infection

Identifiers

PMID31776284
PMCPMC7022352
OpenAlexW2991582275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.